2020.Jul.29
TFDA clearance of passive immunotherapeutic monoclonal antibody OBI-888 for phase I/II human clinical studies
1.Date of occurrence of the event: Jul 29, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4.Reciprocal shareholding ratios: No applicable 5.Cause of occurrence: TFDA clearance of passive immunotherapeutic monoclonal antibody OBI-888 for phase I/II human clinical studies. OBI-888 has completed safety evaluation for phase […]
This article is password protected.
To view the content, please enter your password in the field below